Brown & Brown's Q2 2026 Organic Decline Offset by M&A; Valuation Compresses to Attractive Levels

What happened

Brown & Brown reported a -0.7% organic revenue decline in Q2 2026, a notable reversal from the mid-single-digit growth seen in 2025 amid softening insurance pricing and CAT rates. However, bolt-on acquisitions continued to offset the shortfall, supporting EPS growth and validating the company's inorganic strategy as outlined in the prior DeepValue report. The market has responded by compressing the stock's forward P/E to 15.24, well below its 10-year average and a sharp drop from the ~22.8x trailing multiple when the previous master report was issued in September 2025. Despite the organic headwind, BRO's scale, BBB- credit rating, and disciplined M&A are projected to drive ~7.5% annual EPS growth through 2028, according to the Seeking Alpha article, which reiterates a Buy with a $90 fair value (implying 26% upside). The key question is whether the acquisition engine can sustain growth if organic trends remain weak, but the current valuation provides a margin of safety for investors willing to accept that risk.

Implication

The negative organic growth validates the master report's caution about pricing deceleration, but the M&A offset is evidence of management's ability to adapt. With a forward P/E of 15.24, well below historical and peer averages, the stock offers upside if integration and synergy targets are met. Key risks include further organic deterioration, integration missteps, or a turn in credit markets that limits M&A capacity. Investors should monitor producer retention, synergy realization, and organic growth trends; if organic declines persist, the thesis would weaken despite the low multiple. Overall, the risk/reward appears favorable for patient investors, but the reliance on M&A adds execution risk that must be carefully assessed.

Thesis delta

The thesis shifts slightly negative as BRO's organic growth turned negative in Q2 2026, indicating pricing headwinds are more severe than previously thought. However, the core buy case remains intact due to continued EPS growth from acquisitions, a strong balance sheet, and a materially cheaper valuation (forward P/E 15.24 vs 22.8x trailing a year ago). The next few quarters will be critical to determine if the inorganic strategy can compensate for organic softness, or if a more cautious stance is warranted.